SX-PCK9

N/A

Report date: 2025/01/26 15:50:43

NME

Base Information

Drug NameSX-PCK9

Drug Alias Nameproprotein convertase subtilisin-like/kexin type 9 antagonists (Serometrix)PCSK9 antagonists (Esperion Therapeutics/Serometrix)PCSK9 antagonists (Serometrix)SX-PCK9

ClassificationSmall molecules > Peptidomimetic

Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitorsLDL receptor antagonists

TargetsProprotein convertase subtilisin kexin type 9LDL receptor

Therapy Area/IndicationsHypercholesterolemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSerometrix LLC

China Registration ClassN/A

Develop Information

Active CompaniesEsperion Therapeutics Inc

Inactive CompaniesSerometrix LLC

Active IndicationsHypercholesterolemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A